CLINICAL TRIALS PROFILE FOR NORTHERA
✉ Email this page to a colleague
All Clinical Trials for NORTHERA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00547911 ↗ | Augmenting Effects of L-DOPS With Carbidopa and Entacapone | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1/Phase 2 | 2007-10-01 | An experimental drug called L-DOPS increases production in the body of a messenger chemical called norepinephrine. Cells in the brain that make norepinephrine are often gone in Parkinson disease. The exact consequences of this loss are unknown, but they may be related to symptoms such as fatigue, depression, or decreased attention that occur commonly in Parkinson disease. This study will explore effects of L-DOPS in conjunction with carbidopa and entacapone, which are drugs used to treat Parkinson disease. We wish to find out what the effects are of increasing norepinephrine production in the brain and whether carbidopa and entacapone augment those effects. Volunteers for this study must be at least 18 years of age and able to give consent to participate in the study. To participate in the study, volunteers must discontinue use of alcohol, tobacco, and certain herbal medicines or dietary supplements, and must also taper or discontinue certain kinds of medications that might interfere with the results of the study. Candidates will be screened with a medical history and physical exam. Participants will be admitted to the National Institutes of Health Clinical Center for two weeks of testing. The study will have three testing phases in a randomly chosen order for each participant: - Single dose of L-DOPS - Single dose of L-DOPS in conjunction with carbidopa - Single dose of L-DOPS in conjunction with entacapone Each phase will last two days, with a washout day between each phase in which no drugs will be given and no testing will be performed. In each phase, participants will undergo a series of tests and measurements, including blood pressure and electrocardiogram tests. Participants who are healthy volunteers will also have blood drawn and will undergo a lumbar puncture (also known as a spinal tap) to obtain spinal fluid for chemical tests. |
| NCT00633880 ↗ | Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) | Completed | Chiltern International Inc. | Phase 3 | 2008-01-01 | The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency. |
| NCT00633880 ↗ | Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) | Completed | Chelsea Therapeutics | Phase 3 | 2008-01-01 | The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NORTHERA
Condition Name
Clinical Trial Locations for NORTHERA
Trials by Country
Clinical Trial Progress for NORTHERA
Clinical Trial Phase
Clinical Trial Sponsors for NORTHERA
Sponsor Name
